glimepiride has been researched along with Heart Failure in 9 studies
glimepiride: structure given in first source
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of left ventricular ejection fraction (LVEF) on the behavior of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with heart failure and type 2 diabetes mellitus with the use of canagliflozin compared to glimepiride." | 9.69 | Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial. ( Eguchi, K; Kitada, S; Kodama, K; Node, K; Ohte, N; Seo, Y; Takeishi, Y; Tanaka, A; Teragawa, H; Yamada, T, 2023) |
| "Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure." | 9.51 | Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. ( Imai, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Ozaki, Y; Sata, M; Shimabukuro, M; Tanaka, A, 2022) |
| "A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6." | 9.22 | Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "This study was a post hoc analysis of the CANDLE trial (UMIN000017669), which compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N-terminal pro-brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF)." | 8.31 | Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. ( Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S, 2023) |
| "To investigate the effect of left ventricular ejection fraction (LVEF) on the behavior of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with heart failure and type 2 diabetes mellitus with the use of canagliflozin compared to glimepiride." | 5.69 | Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial. ( Eguchi, K; Kitada, S; Kodama, K; Node, K; Ohte, N; Seo, Y; Takeishi, Y; Tanaka, A; Teragawa, H; Yamada, T, 2023) |
| "Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure." | 5.51 | Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. ( Imai, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Ozaki, Y; Sata, M; Shimabukuro, M; Tanaka, A, 2022) |
| "A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6." | 5.22 | Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "This study was a post hoc analysis of the CANDLE trial (UMIN000017669), which compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N-terminal pro-brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF)." | 4.31 | Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. ( Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S, 2023) |
| "In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups." | 3.11 | Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, A | 6 |
| Imai, T | 2 |
| Shimabukuro, M | 2 |
| Nakamura, I | 1 |
| Matsunaga, K | 1 |
| Ozaki, Y | 1 |
| Minamino, T | 1 |
| Sata, M | 2 |
| Node, K | 6 |
| Nathan, DM | 1 |
| Lachin, JM | 1 |
| Bebu, I | 1 |
| Burch, HB | 1 |
| Buse, JB | 1 |
| Cherrington, AL | 1 |
| Fortmann, SP | 1 |
| Green, JB | 1 |
| Kahn, SE | 1 |
| Kirkman, MS | 1 |
| Krause-Steinrauf, H | 1 |
| Larkin, ME | 1 |
| Phillips, LS | 1 |
| Pop-Busui, R | 1 |
| Steffes, M | 1 |
| Tiktin, M | 1 |
| Tripputi, M | 1 |
| Wexler, DJ | 1 |
| Younes, N | 1 |
| Yamaguchi, S | 1 |
| Hiramitsu, S | 1 |
| Takahashi, N | 1 |
| Kadokami, T | 1 |
| Ajioka, M | 1 |
| Suzuki, M | 2 |
| Ohte, N | 2 |
| Kitada, S | 2 |
| Yamada, T | 2 |
| Eguchi, K | 3 |
| Teragawa, H | 2 |
| Takeishi, Y | 2 |
| Kodama, K | 2 |
| Seo, Y | 2 |
| Nakatani, D | 1 |
| Dohi, T | 1 |
| Hikoso, S | 1 |
| Nanasato, M | 1 |
| Shimizu, W | 2 |
| Sakata, Y | 2 |
| Zhao, C | 1 |
| Jiang, X | 1 |
| Peng, L | 1 |
| Zhang, Y | 1 |
| Li, H | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Yang, F | 1 |
| Wu, J | 1 |
| Wen, Z | 1 |
| He, Z | 1 |
| Shen, J | 1 |
| Chen, C | 1 |
| Wang, DW | 1 |
| Inoue, T | 1 |
| Kitakaze, M | 1 |
| Oyama, J | 1 |
| Taguchi, I | 1 |
| Watada, H | 1 |
| Tomiyama, H | 1 |
| Ako, J | 1 |
| Anzai, T | 1 |
| Uematsu, M | 1 |
| Yamashina, A | 1 |
| Saito, Y | 1 |
| Sato, Y | 1 |
| Ueda, S | 1 |
| Murohara, T | 1 |
| Andersson, C | 1 |
| Gislason, GH | 1 |
| Jørgensen, CH | 1 |
| Hansen, PR | 1 |
| Vaag, A | 1 |
| Sørensen, R | 1 |
| Mérie, C | 1 |
| Olesen, JB | 1 |
| Weeke, P | 1 |
| Schmiegelow, M | 1 |
| Norgaard, ML | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Skugor, M | 1 |
| Siraj, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143] | Phase 3 | 5,047 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for glimepiride and Heart Failure
4 other studies available for glimepiride and Heart Failure
| Article | Year |
|---|---|
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperinsulinism; H | 2023 |
Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
Topics: Animals; Eicosanoids; Epoxide Hydrolases; Heart; Heart Failure; Humans; Mice | 2023 |
Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Female; Glipizide; Glyburide; Heart Failure; Humans; Hyp | 2011 |
A diabetic woman with worsening heart failure, hunger, and tremor.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gastrointestinal Agents; Heart Failure; Humans; Hy | 2003 |